Brivanib alaninate

CHF 0.00
In stock
SYN-1135-M0011 mgCHF 206.00
SYN-1135-M0055 mgCHF 341.00
SYN-1135-M01010 mgCHF 497.00
SYN-1135-M05050 mgCHF 1'277.00
SYN-1135-M100100 mgINQ
More Information
Product Details
Synonyms BMS-582664
Product Type Chemical
Formula C22H24FN5O4
MW 441.5
CAS 649735-63-7
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: FGFR | Kinase Group: RTK | Substrate: Tyrosine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Brivanib inhibits VEGFR-2 with an IC(50) of 25nM and a Ki of 26nM, VEGFR-1 with an IC(50) of 380nM and VEGFR-3 with an IC(50) of 10nM. It also shows selectivity for FGFR-1 with an IC(50) of 148nM, FGFR-2 with an IC(50) of 25nM and FGFR-3 with an IC(50) of 68nM.
Product References
  1. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist: M. Ayers, et al.; Cancer Res. 67, 6899 (2007)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.